The emerging shape of a global HIV research agenda: How partnerships between Northern and Southern researchers are addressing questions relevant to both

Current Opinion in HIV and AIDS

Volumn 3, Issue 4, 2008, Pages 521-525

  Mgone, Charles ^a  

^a European & Developing Countries Clinical Trials Partnership   (Netherlands)

Author keywords

HIV AIDS; Mutual benefit; North South partnerships

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 CANARYPOX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; HEALTH CARE; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; TRAINING;

EID: 67649625468     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283025e3d     Document Type: Review

References (38)

1. Bosch X. Europe and Africa forge new reliance against poverty-related disease. Lancet 2002; 359:1588.
2. Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet 2008; 8:82-83.
3. Sekaly R-P. The failed Merck vaccine study: a step back or launching point for future vaccine development? J Exp Med 2008; 205:7-12.
4. STEP study: disappointing, but not a failure. Lancet 2007; 370:1665.
5. Wilson JM. A call to action. Human Gene Ther 2007; 18:1181.
6. Shiver JW, Fu T-M, Chen L, et al. Replication-incompetent adenoviral vaccine elicits effective antiimmunodeficiency-virus immunity. Nature 2002; 415: 272-273.
7. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccine using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-372.
8. Casimiro DR, Bett AJ, Fu T-M, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replicationdefective adenovirus and poxvirus vaccine vectors. J Virol 2004; 78:11434-11438.
9. Girard MP. The Quest for an HIV vaccine. Bull Acad Natl Med 2005; 189: 831-844.
10. Berkley SF, Koff WC. Scientific and policy challenges to the development of an AIDS vaccine. Lancet 2007; 370:94-101. Understanding of the rationale of immune responses to HIV is important in choosing HIV preventive vaccine strategy. Most current vaccines are based onCMI responses. The paper revises this rationale and attempts to determine broadly neutralizing antibody-based candidate vaccines.
11. BurtonDR,Desrosiers,DomsRW,et al. HIV vaccine design and the neutralising antibody problem. Nat Immunol 2004; 5:133-236.
12. Mascola JR. Defining the protective antibody response for HIV-1. Curr Mol Med 2003; 3:209-216.
13. Pantophlet R, Burton DR. GP120: target for neutralising HIV-1 antibodies. Annu Rev immunol 2006; 24:739-769.
14. Grundner C, Li Y, Louder M, et al. Analysis of the neutralising antibody response elicited in rabbits by repeated inoculations with trimeric HIV-1 envelope glycoproteins. Virology 2005; 331:33-46.
15. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003; 77:5889-5901.
16. Fouts T, Gofrey K, Bobb K, et al. Crossed linked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralising antibodies in rhesus macaques. Proc Natl Acad Sci U S A 2002; 99:11842-11847.
17. Zhou T, Xu L, Dey B, et al. Structural definition of a concerned neutralization epitope on aHIV-1 gp120. Nature 2007; 445:732-737.
18. Calarese DA, Lee HK, Huang CY, et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005; 102:13372-13377.
19. Cardoso RM, Zwick MB, Stanfield RL, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22:163-173.
20. Fitzgerald DW, Marotte C, Verdier RI, et al. Comprehension during informed consent in a less-developed country. Lancet 2002; 360:1301-1302.
21. Fitzgerald DW, Pape JW, Wasserheit JN, et al. Provision of treatment in HIV-1 vaccine trials in developing countries. Lancet 2003; 362:993-994.
22. Cleghorn F, Pape JW, Schecher M, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rpg120. J Acqur Immune Defic Syndr 2007; 46:222-230. Project management in multicountry and multisite setting is very challenging, especially with issues such as synchronization of recruitment and ethical and regulatory approvals. Capacity development to bring all centres in one page may be necessary.
23. Dicko M, Mihigo R, Onyeze A, et al. Strengthening vaccines regulatory capacity in Africa. Geneva: WHO; 2007.
24. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cell induced by vaccination. J Immunol Methods 2007; 323:39-54. Standardization and optimization of ICS is important for comparing HIV candidate vaccines that are based on CMI platform.
25. WHO/UNAIDS/AAVP International Expert Group. Executive summary and recommendations from WHO/UNAIDS and AAVP consultation on: 'The inclusion of adolescents in HIV vaccine trials', 16-18 March 2006 in Gaborone, Botswana. AIDS 2007; 21:W1-W10.
26. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. AIDS 2007; 21:539-546. Joint planning is essential for a global HIV preventive vaccine. Nomenclature is often confusing. This paper discusses standardization of terminology used in vaccine trials.
27. Schneider H, Blaauw D, Gilson L, et al. Health systems and access to antiretoviral drugs for HIV in Southern Africa: service delivery and human resource challenges. Reprod Health Matters 2006; 14:24-26.
28. Fischer A, Karasi JC, Kibibi D, et al. Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: real-life situation in 2002. HIV Med 2006; 7:64-66.
29. Shekelle P, Maglione M, Geotz MB, et al. Antiretroviral drug resistance in the developing world. Evid Rep Technol Assess 2007; 156:1-74.
30. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Study Group. Cohort profile: antiretroviral therapy in lower income countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005; 34:979-986.
31. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-i1-infected patients in the first year of antiretoviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
32. Tuboi SH, Brinkhof MW, Egger M, et al. Discordant responses to potent antiretroviral treatment in previously naïve HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45:52-59.
33. Einterz RM, Kimaiyo S, Mengech HNK, et al. Responding to HIV pandemic: the power of an academic medical partnership. Acad Med 2007; 82:812-818. This paper provides a good example of how academic institutions can deliver their three main objectives: training, research and healthcare for the benefit of the community.
34. Griensven F, Kalichan SC. Design and concept of the NIMH collaborative HIV/STD prevention trial. AIDS 2007; 21 (Suppl 2):S1-S2.
35. NIMH Collaborative HIV/STD Prevention Trial Group. Methodological overview of a five-country community-level HIV/sexually transmitted disease prevention trial. AIDS 2007; 21 (Suppl 2):S3-S18.
36. Sinanovic E, Kumaranayake L. Sharing the burden of TB/HIV? Costs and financing of public-private partnerships for tuberculosis treatment in South Africa. Trop Med Int Research 2006; 11:1466-1674.
37. Ramiah T, Reivh MR. Building effective public-private partnerships: experience and lessons from the African comprehensive HIV/AIDS partnership (ACHAP). Soc Sci Med 2006; 63:397-408.
38. Vian T, Richards SC, McCoy K, et al. Public-private partnerships to build human capacity in low income countries: findings from the Pfizer program. Hum Resour Health 2007; 5:8.1-8.11.